News
The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Click ...
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...
Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...
Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.
Objectives: We reviewed asthma coexistence and the selection of biologic therapies in CRSwNP Management. Methods: The literature review utilized Google and Google Scholar, in addition to PubMed, EBSCO ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...
Data were derived from Walrave L, et al. Abstract 920: Mepolizumab is efficacious in patients with chronic rhinosinusitis with nasal polyps (CRSWNP) with one or multiple prior nasal polyps (NP ...
Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyposis (CRSwNP) and seasonal allergic rhinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results